Home » Stocks » VYNT

Vyant Bio, Inc. (VYNT)

Stock Price: $3.96 USD 0.02 (0.51%)
Updated Jun 17, 2021 1:50 PM EDT - Market open
Market Cap 114.20M
Revenue (ttm) 4.55M
Net Income (ttm) -14.19M
Shares Out 3.18M
EPS (ttm) -4.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $3.96
Previous Close $3.94
Change ($) 0.02
Change (%) 0.51%
Day's Open 3.88
Day's Range 3.85 - 4.05
Day's Volume 256,480
52-Week Range 2.11 - 17.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnolo...

4 weeks ago - GlobeNewsWire

CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technol...

1 month ago - GlobeNewsWire

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

Other stocks mentioned: RXDX, THMO
1 month ago - Benzinga

New collaboration mitigates risk in drug d iscovery process with artificial intelligence and in vitro “avatar” clinical trials

1 month ago - GlobeNewsWire

CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-bas...

2 months ago - GlobeNewsWire

CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-base...

2 months ago - GlobeNewsWire

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

Other stocks mentioned: CGIX
2 months ago - GlobeNewsWire

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline o...

Other stocks mentioned: CGIX
2 months ago - GlobeNewsWire

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...

Other stocks mentioned: CGIX
3 months ago - GlobeNewsWire

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...

Other stocks mentioned: CGIX
3 months ago - GlobeNewsWire

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
4 months ago - GlobeNewsWire

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
4 months ago - GlobeNewsWire

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...

Other stocks mentioned: USNA, ABCL, AZRX, CGIX
4 months ago - Benzinga

Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's premarket...

Other stocks mentioned: CGIX
4 months ago - InvestorPlace

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
4 months ago - GlobeNewsWire

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
4 months ago - GlobeNewsWire

RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief E...

Other stocks mentioned: CGIX
5 months ago - GlobeNewsWire

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. ("CGIX" or the "C...

Other stocks mentioned: CGIX
7 months ago - PRNewsWire

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced toda...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology ser...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services, announc...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

MUMBAI, India and LONDON, Sept. 28, 2020 /PRNewswire/ -- A landmark study published in the American Association of Cancer Research's (AACR) prestigious journal 'Cancer Prevention Research' has shown tha...

Other stocks mentioned: CGIX
8 months ago - PRNewsWire

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger wi...

Other stocks mentioned: CGIX
8 months ago - PRNewsWire

RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today annou...

Other stocks mentioned: CGIX
9 months ago - GlobeNewsWire

RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and St...

Other stocks mentioned: CGIX
9 months ago - GlobeNewsWire

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York Cit...

Other stocks mentioned: CGIX
9 months ago - PRNewsWire

NEW YORK, Aug. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc.

Other stocks mentioned: CGIX
9 months ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Other stocks mentioned: CGIX
9 months ago - Business Wire

Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A.

Other stocks mentioned: CGIX
9 months ago - Newsfile Corp

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc.

Other stocks mentioned: CGIX
9 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cancer Genetics, Inc.

Other stocks mentioned: CGIX
9 months ago - Newsfile Corp

Cancer Genetics (NASDAQ: CGIX) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX.

Other stocks mentioned: CGIX
9 months ago - Benzinga

Cancer Genetics Inc. (NASDAQ: CGIX) shares more than doubled on Monday after the company announced a merger with StemoniX.

Other stocks mentioned: CGIX
9 months ago - 24/7 Wall Street

Cancer Genetics' news of a merger with major drug developer StemoniX has CGIX stock skyrocketing higher on Monday morning. The post Cancer Genetics News: Why CGIX Stock Is Rocketing Today appeared first...

Other stocks mentioned: CGIX
9 months ago - InvestorPlace

Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions

Other stocks mentioned: CGIX
9 months ago - GlobeNewsWire

RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ye...

Other stocks mentioned: CGIX
10 months ago - GlobeNewsWire

Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings and capital...

Other stocks mentioned: AHCO, ARAV, CGIX, GNUS, NOVA, PAYS, RMBL
11 months ago - 24/7 Wall Street

RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announ...

Other stocks mentioned: CGIX
11 months ago - GlobeNewsWire

RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology s...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, f...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

Note Payment Received from Interpace Diagnostics Group, Inc.

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will ...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, f...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

Cancer Genetics (NASDAQ: CGIX) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG) said it purchased the Biopharma Services unit of the Cancer Genetics.

Other stocks mentioned: CGIX
1 year ago - Benzinga

About VYNT

Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers... [Read more...]

Industry
Biotechnology
IPO Date
Apr 5, 2013
CEO
John Roberts
Employees
77
Stock Exchange
NASDAQ
Ticker Symbol
VYNT
Full Company Profile

Financial Performance

In 2020, Vyant Bio's revenue was $5.75 million, a decrease of -21.27% compared to the previous year's $7.31 million. Losses were -$8.00 million, 19.3% more than in 2019.

Financial Statements